Type 2 diabetes mellitus control and atherosclerosis prevention in a non-obese rat model using duodenal-jejunal bypass

Experimental and Therapeutic Medicine

Volumn 8, Issue 3, 2014, Pages 856-862

  Chen, Xuan ^a   Huang, Zhen ^a   Ran, Wenhua ^a   Liao, Gang ^a   Zha, Lang ^a   Wang, Ziwei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Duodenal jejunal bypass; Nuclear factor b; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; I KAPPA B KINASE BETA; INSULIN; LIPID; STRESS ACTIVATED PROTEIN KINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD SAMPLING; CONTROLLED STUDY; DUODENAL JEJUNAL BYPASS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; HISTOLOGY; INFLAMMATION; INTESTINE SURGERY; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RADIOIMMUNOPRECIPITATION; RAT; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; WESTERN BLOTTING;

EID: 84904381317     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1832     Document Type: Article

References (36)

1. Shinde J, Tadldone T, Barletta M, et al. Alpha-glucosidase inhibitory activity of Syzygium cumini (Linn.) Skeels seed kernel in vitro and in Goto-Kakizaki (GK) rats. Carbohydr Res 343: 1278-1281, 2008.
2. Foley EF, Benotti PN, Borlase BC, Hollingshead J and Blackburn GL: Impact of gastric restrictive surgery on hypertension in the morbidly obese. Am J Surg 163: 294-297, 1992.
3. Pories WJ, Swanson MS, MacDonald KG, et al: Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222: 339-350, 1995.
4. Smith SC, Edwards CB and Goodman GN: Changes in diabetic management after Roux-en-Y gastric bypass. Obes Surg 6: 345-348, 1996.
5. Adams TD, Gress RE, Smith SC, et al: Long-term mortality after gastric bypass surgery. N Engl J Med 357: 753-761, 2007.
6. Batsis JA, Sarr MG, Collazo-Clavell ML, et al: Cardiovascular risk after bariatric surgery for obesity. Am J Cardiol 102: 930-937, 2008.
7. Christou NV, Lieberman M, Sampalis F and Sampalis JS: Bariatric surgery reduces cancer risk in morbidly obese patients. Surg Obes Relat Dis 4: 691-695, 2008.
8. Shah SS, Todkar JS, Shah PS and Cummings DE: Diabetes remission and reduced cardiovascular risk after gastric bypass in Asian Indians with body mass index <35 kg/m2. Surg Obes Relat Dis 6: 332-338, 2010.
9. 2: an integrative review of early studies. Obes Surg 20: 776-790, 2010.
10. Rubino F and Marescaux J: Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 239: 1-11, 2004.
11. Cefalu WT: Animal models of type 2 diabetes: clinical presentation and pathophysiological relevance to the human condition. ILAR J 47: 186-198, 2006.
12. ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, et al: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560-2572, 2008.
13. Duckworth W, Abraira C, Moritz T, et al: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360: 129-139, 2009.
14. Athyros VG, Tziomalos K, Karagiannis A and Mikhailidis DP: Preventing macrovascular complications of diabetes: where do we stand with glycemic control? Expert Opin Investig Drugs 17: 1777-1779, 2008.
15. Kyriakis JM and Avruch J: Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev 92: 689-737, 2012.
16. Pamukcu B, Lip GY and Shantsila E: The nuclear factor - kappa B pathway in atherosclerosis: a potential therapeutic target for atherothrombotic vascular disease. Thromb Res 128: 117-123, 2011.
17. Madonna R and De Caterina R: Relevance of new drug discovery to reduce NF-κB activation in cardiovascular disease. Vascul Pharmacol 57: 41-47, 2012.
18. Cuhlmann S, Van der Heiden KV, Saliba D, et al: Disturbed blood flow induces RelA expression via c-Jun N-terminal kinase 1: a novel mode of NF-κB regulation that promotes arterial inflammation. Circ Res 108: 950-959, 2011.
19. Zhang M, Lv XY, Li J, Xu ZG and Chen L: The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp Diabetes Res 2008: 704045, 2008.
20. National Institutes of Health. Guide for the Care and Use of Laboratory Animals. National Institutes of Health publication, no. 85-23, revised in 1985.
21. Rubino F, Forgione A, Cummings DE, et al: The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 244: 741-749, 2006.
22. Laferrère B, Teixeira J, McGinty J, et al: Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 93: 2479-2485, 2008.
23. Cohen RV, Schiavon CA, Pinheiro JS, Correa JL and Rubino F: Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22-34 kg/m2: a report of 2 cases. Surg Obes Relat Dis 3: 195-197, 2007.
24. Gumbs AA, Modlin IM and Ballantyne GH: Changes in insulin resistance following bariatric surgery: role of caloric restriction and weight loss. Obes Surg 15: 462-473, 2005.
25. Mingrone G, Panunzi S, De Gaetano AD, et al: Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366: 1577-1585, 2012.
26. Schauer PR, Kashyap SR, Wolski K, et al: Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 366: 1567-1576, 2012.
27. Pournaras DJ, Osborne A, Hawkins SC, et al: Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann Surg 252: 966-971, 2010.
28. Rubino F and Gagner M: Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 236: 554-559, 2002.
29. Buchwald H and Williams SE: Bariatric surgery worldwide 2003. Obes Surg 14: 1157-1164, 2004.
30. Scopinaro N, Marinari GM, Camerini GB, Papadia FS and Adami GF: Specfic effects of biliopancreatic diversion on the major components of metabolic syndrome:a long-term follow-up study. Diabetes Care 28: 2406-2411, 2005.
31. Kaneto H, Matsuoka TA, Katakami N, et al: Oxidative stress and the JNK pathway are involved in the development of type 1 and type 2 diabetes. Curr Mol Med 7: 674-686, 2007.
32. Li JJ and Fang CH: C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses 62: 499-506, 2004.
33. Lou Y, Liu S, Zhang C, et al: Enhanced atherosclerosis in TIPE2-deficient mice is associated with increased macrophage responses to oxidized low-density lipoprotein. J Immunol 191: 4849-4857, 2013.
34. Lee YJ, Kim JS, Kang DG and Lee HS: Buddleja officinalis suppresses high glucose-induced vascular smooth muscle cell proliferation: role of mitogen-activated protein kinases, nuclear factor-kappaB and matrix metalloproteinases. Exp Biol Med (Maywood) 235: 247-255, 2010.
35. DiGiorgi M, Rosen DJ, Choi JJ, et al: Re-emergence of diabetes after gastric bypass in patients with mid-to long-term follow-up. Surg Obes Relat Dis 6: 249-253, 2010.
36. Arterburn DE, Bogart A, Sherwood NE, et al: A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 23: 93-102, 2013.